Eton Pharmaceuticals, Inc. (ETON) fair value analysis
Nasdaq · Updated 2026-09-07
Eton Pharmaceuticals, Inc. is a pharmaceutical company that develops and commercializes specialty drugs focused on treating rare and orphan diseases. The company operates in the United States.
Valuation status
Awaiting full valuationETON does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $45.14
- Sector
- Healthcare
- 12-month range
- $15.17–$45.14
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Moderate
- RSI zone
- Neutral
- 50/200-day trend
- Mixed
- 52-week position
- The top quarter of its range
What our data shows for ETON
- Our model validated 2 trailing price-to-earnings windows for ETON, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $15.17–$45.14.
- The 14-day relative strength index sits at a neutral 60.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ETON
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent ETON news
TickrTrends' derived news-sentiment signal for ETON is currently leaning negative, computed from recent coverage.
- Morning Market Movers: WETO, CAPR, AKAN, DAAQ See Big Swings (rttnews.com, 2026-08-14)
TickrTrends take: ETON was not specifically mentioned in this morning's market movers report, which focused on WETO, CAPR, AKAN, and DAAQ. Given that TickrTrends currently shows an awaiting full valuation status for this healthcare company, investors interested in the sector should monitor whether ETON experiences similar volatility patterns to other stocks experiencing significant swings today. The absence of ETON from the active movers list may reflect different trading dynamics or investor sentiment compared to the highlighted names, which could be relevant context as its valuation analysis develops. - Eton Pharmaceuticals forecasts 2026 revenue to exceed $145M while targeting adjusted EBITDA margin above 35% (NASDAQ:ETON) (seekingalpha.com, 2026-08-14)
What people are saying
Follow the ETON conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — ETON in the Healthcare sector has experienced a shift in its trend state this week, with the 50/200-day trend moving from an uptrend to a mixed condition. This change reflects recent price action that has altered the relationship between shorter and longer-term moving averages. The full valuation assessment for ETON remains pending pending additional analysis.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is ETON stock undervalued?
ETON does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is ETON's TickrTrends verdict?
ETON is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is ETON overbought or oversold?
ETON's 14-day RSI is in neutral territory - neither overbought nor oversold.